CO2019014090A2 - Agentes, usos y métodos para el tratamiento - Google Patents
Agentes, usos y métodos para el tratamientoInfo
- Publication number
- CO2019014090A2 CO2019014090A2 CONC2019/0014090A CO2019014090A CO2019014090A2 CO 2019014090 A2 CO2019014090 A2 CO 2019014090A2 CO 2019014090 A CO2019014090 A CO 2019014090A CO 2019014090 A2 CO2019014090 A2 CO 2019014090A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- agents
- methods
- antibodies
- pgrn
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 2
- 102000019204 Progranulins Human genes 0.000 abstract 2
- 108010012809 Progranulins Proteins 0.000 abstract 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Psychiatry (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201700419 | 2017-07-20 | ||
PCT/EP2018/069460 WO2019016247A2 (en) | 2017-07-20 | 2018-07-18 | AGENTS, USES AND METHODS OF TREATMENT |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019014090A2 true CO2019014090A2 (es) | 2020-01-17 |
Family
ID=63113476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0014090A CO2019014090A2 (es) | 2017-07-20 | 2019-12-13 | Agentes, usos y métodos para el tratamiento |
Country Status (24)
Country | Link |
---|---|
US (2) | US10894833B2 (ja) |
EP (1) | EP3655438A2 (ja) |
JP (2) | JP2020527152A (ja) |
KR (1) | KR20200031610A (ja) |
AR (1) | AR112563A1 (ja) |
AU (1) | AU2018303175A1 (ja) |
BR (1) | BR112019005428A2 (ja) |
CA (1) | CA3069391A1 (ja) |
CL (1) | CL2020000070A1 (ja) |
CO (1) | CO2019014090A2 (ja) |
CR (1) | CR20200027A (ja) |
DO (1) | DOP2020000006A (ja) |
EA (1) | EA201992688A1 (ja) |
EC (1) | ECSP20002935A (ja) |
IL (1) | IL271728B2 (ja) |
JO (1) | JOP20200007A1 (ja) |
MA (1) | MA49633A (ja) |
NI (1) | NI202000005A (ja) |
PE (1) | PE20210467A1 (ja) |
PH (1) | PH12019502869A1 (ja) |
RU (1) | RU2019140933A (ja) |
SG (1) | SG11201912228WA (ja) |
TW (1) | TW201908342A (ja) |
WO (1) | WO2019016247A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3991748A3 (en) | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
SI3618928T1 (sl) | 2018-07-13 | 2023-04-28 | Alector Llc | Protitelesa proti sortilinu in postopki za uporabo le-teh |
SG11202108398YA (en) * | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
CN116249717A (zh) * | 2020-06-24 | 2023-06-09 | 普罗塞纳生物科学有限公司 | 识别分拣蛋白的抗体 |
WO2023247754A1 (en) | 2022-06-23 | 2023-12-28 | Draupnir Bio Aps | Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
EP0486622B1 (en) | 1989-08-09 | 1998-11-04 | Rhomed, Incorporated | Direct radiolabeling of antibodies and other proteins with technetium or rhenium |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5101990A (en) | 1990-03-23 | 1992-04-07 | Continental Pet Technologies, Inc. | Stretch blow molded oblong or oval container |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
JPH06508880A (ja) | 1991-07-08 | 1994-10-06 | ユニバーシティ オブ マサチューセッツ アット アムハースト | サーモトロピック液晶セグメント化ブロックコポリマー |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
AU693436B2 (en) | 1993-03-09 | 1998-07-02 | Genzyme Corporation | Isolation of components of interest from milk |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
MXPA01007895A (es) | 1999-02-03 | 2003-07-21 | Biosante Pharmaceuticals Inc | Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos. |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
AU6375000A (en) | 1999-07-29 | 2001-02-19 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
US6881557B2 (en) | 2001-07-12 | 2005-04-19 | Arrowsmith Technologies Llp | Super humanized antibodies |
WO2004056385A2 (en) | 2002-12-20 | 2004-07-08 | Neuronicon Aps | Modulation of activity of neurotrophins |
SG10201600950TA (en) | 2005-11-28 | 2016-03-30 | Genmab As | Recombinant monovalent antibodies and methods for production thereof |
WO2008076262A2 (en) | 2006-12-15 | 2008-06-26 | Merck & Co., Inc. | Receptor for amyloid beta and uses thereof |
SI3225251T1 (sl) | 2006-12-21 | 2020-03-31 | H. Lundbeck A/S | Modulacija aktivnosti pronevrotrofinov |
EP2185692A4 (en) | 2007-08-10 | 2012-05-02 | Medarex Inc | HCO32 AND HCO27 AND RELATED EXAMPLES |
US8377701B2 (en) | 2008-04-27 | 2013-02-19 | H. Lundbeck A/S | Specific ligands to sortilin |
WO2009154995A2 (en) * | 2008-05-27 | 2009-12-23 | Kyowa Hakko Kirin Co., Ltd. | Interleukin 10 receptor (il-10r) antibodies and methods of use |
US20120039865A1 (en) | 2008-08-19 | 2012-02-16 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
CN105641694B (zh) | 2008-12-19 | 2020-08-14 | H.隆德贝克有限公司 | 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节 |
JP6239635B2 (ja) | 2012-11-02 | 2017-11-29 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | 血管石灰化の誘導因子であるソルチリン1 |
EP3991748A3 (en) * | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
SI3618928T1 (sl) * | 2018-07-13 | 2023-04-28 | Alector Llc | Protitelesa proti sortilinu in postopki za uporabo le-teh |
-
2018
- 2018-07-17 US US16/037,790 patent/US10894833B2/en active Active
- 2018-07-18 JP JP2020502415A patent/JP2020527152A/ja active Pending
- 2018-07-18 BR BR112019005428A patent/BR112019005428A2/pt not_active IP Right Cessation
- 2018-07-18 EP EP18750343.8A patent/EP3655438A2/en active Pending
- 2018-07-18 CA CA3069391A patent/CA3069391A1/en active Pending
- 2018-07-18 EA EA201992688A patent/EA201992688A1/ru unknown
- 2018-07-18 SG SG11201912228WA patent/SG11201912228WA/en unknown
- 2018-07-18 WO PCT/EP2018/069460 patent/WO2019016247A2/en unknown
- 2018-07-18 MA MA049633A patent/MA49633A/fr unknown
- 2018-07-18 RU RU2019140933A patent/RU2019140933A/ru unknown
- 2018-07-18 IL IL271728A patent/IL271728B2/en unknown
- 2018-07-18 JO JOP/2020/0007A patent/JOP20200007A1/ar unknown
- 2018-07-18 AU AU2018303175A patent/AU2018303175A1/en active Pending
- 2018-07-18 PE PE2020000100A patent/PE20210467A1/es unknown
- 2018-07-18 KR KR1020207001250A patent/KR20200031610A/ko not_active Application Discontinuation
- 2018-07-18 CR CR20200027A patent/CR20200027A/es unknown
- 2018-07-19 TW TW107124976A patent/TW201908342A/zh unknown
- 2018-07-20 AR ARP180102043 patent/AR112563A1/es unknown
-
2019
- 2019-12-13 CO CONC2019/0014090A patent/CO2019014090A2/es unknown
- 2019-12-18 PH PH12019502869A patent/PH12019502869A1/en unknown
-
2020
- 2020-01-09 DO DO2020000006A patent/DOP2020000006A/es unknown
- 2020-01-09 CL CL2020000070A patent/CL2020000070A1/es unknown
- 2020-01-16 EC ECSENADI20202935A patent/ECSP20002935A/es unknown
- 2020-01-17 NI NI202000005A patent/NI202000005A/es unknown
- 2020-12-11 US US17/118,934 patent/US20210292414A1/en active Pending
-
2024
- 2024-05-28 JP JP2024085982A patent/JP2024119866A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112019005428A2 (pt) | 2019-07-16 |
EP3655438A2 (en) | 2020-05-27 |
IL271728B1 (en) | 2024-01-01 |
RU2019140933A (ru) | 2021-08-20 |
CA3069391A1 (en) | 2019-01-24 |
MA49633A (fr) | 2020-05-27 |
US10894833B2 (en) | 2021-01-19 |
WO2019016247A2 (en) | 2019-01-24 |
CR20200027A (es) | 2020-04-17 |
ECSP20002935A (es) | 2020-02-28 |
US20210292414A1 (en) | 2021-09-23 |
NI202000005A (es) | 2020-05-20 |
US20190023788A1 (en) | 2019-01-24 |
WO2019016247A3 (en) | 2019-06-20 |
EA201992688A1 (ru) | 2020-05-20 |
IL271728A (en) | 2020-02-27 |
TW201908342A (zh) | 2019-03-01 |
KR20200031610A (ko) | 2020-03-24 |
CL2020000070A1 (es) | 2020-06-12 |
AR112563A1 (es) | 2019-11-13 |
JOP20200007A1 (ar) | 2020-01-15 |
PH12019502869A1 (en) | 2020-09-28 |
CN110945029A (zh) | 2020-03-31 |
AU2018303175A1 (en) | 2020-01-16 |
JP2024119866A (ja) | 2024-09-03 |
IL271728B2 (en) | 2024-05-01 |
PE20210467A1 (es) | 2021-03-08 |
JP2020527152A (ja) | 2020-09-03 |
RU2019140933A3 (ja) | 2021-10-28 |
DOP2020000006A (es) | 2020-07-15 |
SG11201912228WA (en) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019014090A2 (es) | Agentes, usos y métodos para el tratamiento | |
MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
CO2017012988A2 (es) | Agentes, usos y métodos para el tratamiento | |
MA44322A (fr) | Compositions comprenant des souches bactériennes | |
MA42471A (fr) | Compositions comprenant des souches bactériennes | |
DOP2016000195A (es) | Compuestos | |
SA519400950B1 (ar) | Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة | |
GEP20207151B (en) | Agents, Uses and Methods for the Treatment of Synucleinopathy | |
UY37808A (es) | Nuevos compuestos que inhiben la actividad quinasa de la lrrk2 | |
MD3261720T2 (ro) | Anticorpi anti-Tau și utilizările acestora | |
MX2022015248A (es) | Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn. | |
UY37580A (es) | Compuestos novedosos que inhiben la actividad de cinasa lrrk2 | |
MX2017012397A (es) | Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache). | |
MY184878A (en) | Compositions and methods for treating neurodegenerative diseases | |
MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
MX2020006140A (es) | Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas. | |
CR20220228A (es) | Anticuerpos trem2 y usos de estos | |
MX2017006692A (es) | Trastornos neurodegenerativos. | |
PH12021550213A1 (en) | Methods for treating neurodegenerative disorders | |
MX2019001804A (es) | Peptidos modificados para uso en el tratamiento de trastornos neurodegenerativos. | |
MA40908B1 (fr) | Anticorps anti-il-6 améliorés | |
EA201792076A1 (ru) | Методы и композиции для внутривенного введения фумаратов для лечения неврологических заболеваний |